These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7037441)

  • 41. The effects of Lampit (Bayer 2502) on the interaction of Trypanosoma cruzi with vertebrate cells in vitro.
    Dvorak JA; Howe CL
    Am J Trop Med Hyg; 1977 Jan; 26(1):58-63. PubMed ID: 320896
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A method to assess invasion and intracellular replication of Trypanosoma cruzi based on differential uracil incorporation.
    Yan W; Moreno SN
    J Immunol Methods; 1998 Nov; 220(1-2):123-8. PubMed ID: 9839933
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of nifurtimox on Trypanosoma cruzi in tissue cultures.
    Gönnert R; Bock M
    Arzneimittelforschung; 1972 Sep; 22(9):1582-6. PubMed ID: 4567080
    [No Abstract]   [Full Text] [Related]  

  • 44. [Detection of Trypanosoma cruzi by hemoculture in patients with chronic Chagas' disease].
    Basso B; Moretti ER
    Medicina (B Aires); 1984; 44(1):41-7. PubMed ID: 6443013
    [No Abstract]   [Full Text] [Related]  

  • 45. [Inhibition of oxidative phosphorylation in Crithidia fasciculata and Trypanosoma cruzi by lipophilic o-quinones and nifurtimox].
    Biscardi AM; Fernandez Villamil SH; Stoppani AO
    Rev Argent Microbiol; 1994; 26(2):72-86. PubMed ID: 7938505
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox.
    Murta SM; Gazzinelli RT; Brener Z; Romanha AJ
    Mol Biochem Parasitol; 1998 Jun; 93(2):203-14. PubMed ID: 9662705
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Automated high-content assay for compounds selectively toxic to Trypanosoma cruzi in a myoblastic cell line.
    Alonso-Padilla J; Cotillo I; Presa JL; Cantizani J; Peña I; Bardera AI; Martín JJ; Rodriguez A
    PLoS Negl Trop Dis; 2015 Jan; 9(1):e0003493. PubMed ID: 25615687
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Effect of redox potential on culture parameters of Trypanosoma cruzi developed in liquid stirred media].
    Martínez RA; Guerrero SA; Miglietta HF
    Rev Argent Microbiol; 2005; 37(4):165-8. PubMed ID: 16502634
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro and in vivo anti-Trypanosoma cruzi activity of a novel nitro-derivative.
    Muelas-Serrano S; Le-Senne A; Fernandez-Portillo C; Nogal JJ; Ochoa C; Gomez-Barrio A
    Mem Inst Oswaldo Cruz; 2002 Jun; 97(4):553-7. PubMed ID: 12118290
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The efficacy of a novel compound, (e)-1-(4'-bromo-4-biphenylyl)-1-(4-chlorophenyl)-3-dimethylaminoprop-1-ene against Trypanosoma cruzi in mice.
    Barrett PA; Beveridge E; Bull D; Caldwell IC; Islip PJ; Neal RA; Woods NC
    Experientia; 1982 Mar; 38(3):338-9. PubMed ID: 6804255
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of nitroheterocyclic drugs on macromolecule synthesis and degradation in Trypanosoma cruzi.
    Goijman SG; Stoppani AO
    Biochem Pharmacol; 1985 Apr; 34(8):1331-6. PubMed ID: 2581582
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New potent 5-substituted benzofuroxans as inhibitors of Trypanosoma cruzi growth: quantitative structure-activity relationship studies.
    Aguirre G; Boiani L; Boiani M; Cerecetto H; Di Maio R; González M; Porcal W; Denicola A; Piro OE; Castellano EE; Sant'Anna CM; Barreiro EJ
    Bioorg Med Chem; 2005 Dec; 13(23):6336-46. PubMed ID: 16202608
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Disposition of nifurtimox and metabolite activity against Trypanosoma cruzi using rat isolated perfused liver.
    González-Martin G; Paulos C; Guevara A; Ponce G
    J Pharm Pharmacol; 1994 May; 46(5):356-9. PubMed ID: 8083806
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of trypanocidal drugs on protein biosynthesis in vitro and in vivo by Trypanosoma cruzi.
    Gonzalez NS; Cazzulo JJ
    Biochem Pharmacol; 1989 Sep; 38(17):2873-7. PubMed ID: 2673249
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization and trypanocidal activity of nifurtimox-containing and empty nanoparticles of polyethylcyanoacrylates.
    Gonzalez-Martin G; Merino I; Rodriguez-Cabezas MN; Torres M; Nuñez R; Osuna A
    J Pharm Pharmacol; 1998 Jan; 50(1):29-35. PubMed ID: 9580223
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synergistic effects of ketoconazole and SF-86327 on the proliferation of epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi.
    Urbina JA; Lazardi K; Larralde G; Aguirre T; Piras MM; Piras R
    Ann N Y Acad Sci; 1988; 544():357-8. PubMed ID: 3063176
    [No Abstract]   [Full Text] [Related]  

  • 57. Growth of Trypanosoma cruzi in vitro: development and application of a continuous-flow culture system.
    Williams GT; Hudson L
    Parasitology; 1982 Jun; 84(Pt 3):511-26. PubMed ID: 7048212
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rational drug design in parasitology: trans-sialidase as a case study for Chagas disease.
    Neres J; Bryce RA; Douglas KT
    Drug Discov Today; 2008 Feb; 13(3-4):110-7. PubMed ID: 18275908
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drug Discovery for Paediatric Chagas Disease.
    Thota S; Morel CM
    Mini Rev Med Chem; 2018; 18(9):776-780. PubMed ID: 26202205
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Drug resistance in Trypanosoma cruzi is not associated with amplification or overexpression of P-glycoprotein (PGP) genes.
    Murta SM; dos Santos WG; Anacleto C; Nirdé P; Moreira ES; Romanha AJ
    Mol Biochem Parasitol; 2001 Oct; 117(2):223-8. PubMed ID: 11606233
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.